TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of SMS and Interactive Reminders to Improve Timely Immunization Coverage: A Randomized Controlled Trial
Brief Summary: Pakistan has one of the highest infant mortality rates in the world. One child in eleven dies before their fifth birthday. In part, this is due to the low coverage rate of routine childhood immunizations. Since Pakistan is a Low Middle Income Country (LMIC) it is essential that an immunization intervention be developed that is suitable for its socioeconomic setting. The tele-density of Pakistan exceeds 70% and the cost of SMS in Pakistan is very low. Moreover the use of SMS in the country has broadened beyond the conventional use of peer-peer chat to include social networking, SMS banking, delivery tracking, advertising, business, disaster management, and identity verification. This study will utilise this prevalence of mobile phones to assess whether simple and interactive sms reminders can serve to increase childhood immunization coverage and timeliness.

The pilot study will be carried out only in 2 EPI (Extended program on Immunization) centers at Korangi. The pilot will determine whether automated text messages produce increased immunization coverage in the reminder groups compared to the control group. 656 participants will be enrolled at Penta-1 and will be followed up until measles-2 vaccination. The results of proposed pilot will provide the basis for a large scale-up study in urban and rural settings in Pakistan.


Options:
A: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Other: promotional Exclusive breastfeeding text messages | Arm Label: control; Type: OTHER; Interventions: Other: promotional Exclusive breastfeeding text messages | Intervention Type: OTHER; Name: promotional Exclusive breastfeeding text messages; Assigned to Arm(s): control, intervention
B: Arm Label: Text-Based Adherence Game; Type: EXPERIMENTAL; Interventions: Behavioral: Text-Based Adherence Game, Behavioral: Standard of Care (SOC) | Arm Label: Standard of Care (SOC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard of Care (SOC) | Intervention Type: BEHAVIORAL; Name: Text-Based Adherence Game; Assigned to Arm(s): Text-Based Adherence Game | Intervention Type: BEHAVIORAL; Name: Standard of Care (SOC); Assigned to Arm(s): Standard of Care (SOC), Text-Based Adherence Game
C: Arm Label: LATCH Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: LATCH Intervention | Intervention Type: BEHAVIORAL; Name: LATCH Intervention; Assigned to Arm(s): LATCH Intervention
D: Arm Label: SMS Reminder; Type: EXPERIMENTAL; Interventions: Other: SMS Reminder | Arm Label: Interactive Reminder; Type: EXPERIMENTAL; Interventions: Other: Interactive Reminder | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: SMS Reminder; Assigned to Arm(s): SMS Reminder | Intervention Type: OTHER; Name: Interactive Reminder; Assigned to Arm(s): Interactive Reminder

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Evaluation of Efficacy and Safety of a Medical Device for the Treatment of Toenail Onychomycosis.
Brief Summary: This study evaluates the effect of the medical device "Excilor® Forte" in the treatment of toenail onychomycosis. Half of the participants will receive the tested product and the other half will receive a comparator (Amorolfin 5%). Patients will be followed during 6 months.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Low Strength IDP-108 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: High Strength IDP-108 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: High Strength IDP-108 under occlusion | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle | Intervention Type: DRUG; Name: Low Strength IDP-108; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: High Strength IDP-108; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: High Strength IDP-108 under occlusion; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Vehicle; Assigned to Arm(s): 4
B: Arm Label: Excilor Forte; Type: EXPERIMENTAL; Interventions: Device: Excilor Forte | Arm Label: Loceryl 5%; Type: ACTIVE_COMPARATOR; Interventions: Drug: Loceryl 5% | Intervention Type: DEVICE; Name: Excilor Forte; Assigned to Arm(s): Excilor Forte | Intervention Type: DRUG; Name: Loceryl 5%; Assigned to Arm(s): Loceryl 5%
C: Arm Label: Investigator blinded Loceryl NL+ Cosmetic varnish; Type: EXPERIMENTAL; Interventions: Drug: Loceryl NL + Cosmetic varnish, Drug: Loceryl NL 15 months | Arm Label: Investigator blinded Loceryl NL alone; Type: EXPERIMENTAL; Interventions: Drug: Loceryl NL 12 weeks, Drug: Loceryl NL 15 months | Intervention Type: DRUG; Name: Loceryl NL + Cosmetic varnish; Assigned to Arm(s): Investigator blinded Loceryl NL+ Cosmetic varnish | Intervention Type: DRUG; Name: Loceryl NL 12 weeks; Assigned to Arm(s): Investigator blinded Loceryl NL alone | Intervention Type: DRUG; Name: Loceryl NL 15 months; Assigned to Arm(s): Investigator blinded Loceryl NL alone, Investigator blinded Loceryl NL+ Cosmetic varnish
D: Arm Label: IDP-108; Type: EXPERIMENTAL; Interventions: Drug: IDP-108 | Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle | Intervention Type: DRUG; Name: IDP-108; Assigned to Arm(s): IDP-108 | Intervention Type: DRUG; Name: Vehicle; Assigned to Arm(s): Vehicle

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-centered Stepped Wedge Cluster Randomized Controlled Trial of the De-adoption of Oral Chlorhexidine Prophylaxis and Implementation of an Oral Care Bundle for Ventilated Critically Ill Patients
Brief Summary: The objective of the CHORAL study is to evaluate the de-adoption of oral chlorhexidine and the introduction of a bundle of oral care practices on selected outcomes in critically ill mechanically ventilated adults.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: oral hygiene | Intervention Type: OTHER; Name: oral hygiene; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): 1
B: Arm Label: Pre-intubation CHX; Type: EXPERIMENTAL; Interventions: Procedure: Pre-intubation CHX | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Control | Intervention Type: PROCEDURE; Name: Pre-intubation CHX; Assigned to Arm(s): Pre-intubation CHX | Intervention Type: PROCEDURE; Name: Control; Assigned to Arm(s): Control
C: Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine oral care (CHX-Oro), Drug: Selective oropharyngeal decontamination (SOD), Drug: Selective Digestive Decontamination (SDD) | Arm Label: Chlorhexidine oral care (CHX-Oro); Type: EXPERIMENTAL; Interventions: Drug: Chlorhexidine oral care (CHX-Oro) | Arm Label: Selective oropharyngeal decontamination; Type: EXPERIMENTAL; Interventions: Drug: Selective oropharyngeal decontamination (SOD) | Arm Label: Selective digestive decontamination; Type: EXPERIMENTAL; Interventions: Drug: Selective Digestive Decontamination (SDD) | Intervention Type: DRUG; Name: Chlorhexidine oral care (CHX-Oro); Assigned to Arm(s): Chlorhexidine oral care (CHX-Oro), Standard care | Intervention Type: DRUG; Name: Selective oropharyngeal decontamination (SOD); Assigned to Arm(s): Selective oropharyngeal decontamination, Standard care | Intervention Type: DRUG; Name: Selective Digestive Decontamination (SDD); Assigned to Arm(s): Selective digestive decontamination, Standard care
D: Arm Label: Oral Chlorhexidine Mouth Rinse; Type: OTHER; Interventions: Other: Chlorhexidine Mouth Rinse | Arm Label: De-Adoption of Oral Chlorhexidine Mouth Rinse; Type: EXPERIMENTAL; Interventions: Other: Chlorhexidine Mouth Rinse De-Adoption | Intervention Type: OTHER; Name: Chlorhexidine Mouth Rinse; Assigned to Arm(s): Oral Chlorhexidine Mouth Rinse | Intervention Type: OTHER; Name: Chlorhexidine Mouth Rinse De-Adoption; Assigned to Arm(s): De-Adoption of Oral Chlorhexidine Mouth Rinse

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Single Center, Placebo-Controlled Trial of Oral High-Molecular Weight Hyaluronic Acid for the Prevention of Aromatase Inhibitor-Associated Arthralgias
Brief Summary: This is a single center, double-blinded, placebo-controlled, randomized Phase II trial to determine whether oral hyaluronic acid will prevent aromatase inhibitor (AI)-associated arthralgias. Subjects must have ER/PR-positive breast cancer tumor with history of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) which resolved after cessation of their AI (anastrazole or letrozole) within 90 days of enrollment. Subjects will be stratified by initial AI, thus within each initial AI, subjects will be randomized to receive either the experimental treatment (hyaluronic acid) or placebo. Subjects will begin the assigned treatment for 2 weeks prior to transitioning to the second AI. Evaluations will be taken at baseline, 6 weeks (1 month on study drug and AI), 14 weeks (3 months on study drug and AI), and at 26 weeks (6 months on study drug and AI). Treatment with hyaluronic acid and placebo will last for 26 weeks total.


Options:
A: Arm Label: Arm I (omega-3 fatty acid); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Omega-3 Fatty Acid | Arm Label: Arm II (placebo); Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 Fatty Acid; Assigned to Arm(s): Arm I (omega-3 fatty acid) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm II (placebo)
B: Arm Label: Hyaluronic Acid; Type: EXPERIMENTAL; Interventions: Drug: Hyaluronic Acid (HA) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Hyaluronic Acid (HA); Assigned to Arm(s): Hyaluronic Acid | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Arm I/Group A (Duloxetine then Placebo); Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Other: placebo | Arm Label: Arm II/Group B (Placebo then Duloxetine); Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Other: placebo | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Arm I/Group A (Duloxetine then Placebo), Arm II/Group B (Placebo then Duloxetine) | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm I/Group A (Duloxetine then Placebo), Arm II/Group B (Placebo then Duloxetine)
D: Intervention Type: OTHER; Name: aromatase inhibition therapy - OBSERVATIONAL ONLY; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: medical chart review; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: assessment of therapy complications; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2b Randomized, Double-blind, Placebo Controlled, Multi-center 12-week Study With an Additional 40-week Follow-up Assessment of Efficacy, Safety and Tolerability of M1095 in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Brief Summary: This is a multi-center phase 2b study in subjects with moderate to severe chronic plaque-type psoriasis. Approximately 300 subjects will be enrolled at approximately 60 investigator sites in North America and Europe.


Options:
A: Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): N/A
B: Arm Label: M1095 (Sonelokimab) 30mg; Type: EXPERIMENTAL; Interventions: Drug: M1095 (Sonelokimab) | Arm Label: M1095 (Sonelokimab) 60mg; Type: EXPERIMENTAL; Interventions: Drug: M1095 (Sonelokimab) | Arm Label: M1095 (Sonelokimab) 120mg - regimen 1; Type: EXPERIMENTAL; Interventions: Drug: M1095 (Sonelokimab) | Arm Label: M1095 (Sonelokimab) 120mg - regimen 2; Type: EXPERIMENTAL; Interventions: Drug: M1095 (Sonelokimab) | Arm Label: Placebo / M1095 (Sonelokimab) 120mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: M1095 (Sonelokimab), Drug: Placebo | Arm Label: Secukinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab | Intervention Type: DRUG; Name: M1095 (Sonelokimab); Assigned to Arm(s): M1095 (Sonelokimab) 120mg - regimen 1, M1095 (Sonelokimab) 120mg - regimen 2, M1095 (Sonelokimab) 30mg, M1095 (Sonelokimab) 60mg, Placebo / M1095 (Sonelokimab) 120mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo / M1095 (Sonelokimab) 120mg | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): Secukinumab
C: Arm Label: 80 mg Ixekizumab Auto-Injector; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab Auto-Injector | Arm Label: 80 mg Ixekizumab Prefilled Syringe; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab Prefilled Syringe | Intervention Type: DRUG; Name: Ixekizumab Auto-Injector; Assigned to Arm(s): 80 mg Ixekizumab Auto-Injector | Intervention Type: DRUG; Name: Ixekizumab Prefilled Syringe; Assigned to Arm(s): 80 mg Ixekizumab Prefilled Syringe
D: Arm Label: KHK4827 70mg SC; Type: EXPERIMENTAL; Interventions: Drug: KHK4827 | Arm Label: KHK4827 140mg SC; Type: EXPERIMENTAL; Interventions: Drug: KHK4827 | Arm Label: KHK4827 210mg SC; Type: EXPERIMENTAL; Interventions: Drug: KHK4827 | Arm Label: Placebo SC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: KHK4827; Assigned to Arm(s): KHK4827 140mg SC, KHK4827 210mg SC, KHK4827 70mg SC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo SC

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2b Randomized, Double-blind, Placebo Controlled, Multi-center 12-week Study With an Additional 40-week Follow-up Assessment of Efficacy, Safety and Tolerability of M1095 in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Brief Summary: This is a multi-center phase 2b study in subjects with moderate to severe chronic plaque-type psoriasis. Approximately 300 subjects will be enrolled at approximately 60 investigator sites in North America and Europe.


Options:
A: Arm Label: M1095 (Sonelokimab) 30mg; Type: EXPERIMENTAL; Interventions: Drug: M1095 (Sonelokimab) | Arm Label: M1095 (Sonelokimab) 60mg; Type: EXPERIMENTAL; Interventions: Drug: M1095 (Sonelokimab) | Arm Label: M1095 (Sonelokimab) 120mg - regimen 1; Type: EXPERIMENTAL; Interventions: Drug: M1095 (Sonelokimab) | Arm Label: M1095 (Sonelokimab) 120mg - regimen 2; Type: EXPERIMENTAL; Interventions: Drug: M1095 (Sonelokimab) | Arm Label: Placebo / M1095 (Sonelokimab) 120mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: M1095 (Sonelokimab), Drug: Placebo | Arm Label: Secukinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab | Intervention Type: DRUG; Name: M1095 (Sonelokimab); Assigned to Arm(s): M1095 (Sonelokimab) 120mg - regimen 1, M1095 (Sonelokimab) 120mg - regimen 2, M1095 (Sonelokimab) 30mg, M1095 (Sonelokimab) 60mg, Placebo / M1095 (Sonelokimab) 120mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo / M1095 (Sonelokimab) 120mg | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): Secukinumab
B: Arm Label: Bimekizumab cohort; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Bimekizumab Escape arm; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab | Intervention Type: DRUG; Name: Bimekizumab; Assigned to Arm(s): Bimekizumab Escape arm, Bimekizumab cohort | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Bimekizumab cohort, Placebo
C: Arm Label: Adalimumab; Type: OTHER; Interventions: Drug: adalimumab | Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): Adalimumab
D: Arm Label: Adalimumab (Humira); Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab (Humira) | Arm Label: Placebo Injection; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Injection | Arm Label: NB-UVB phototherapy; Type: ACTIVE_COMPARATOR; Interventions: Other: NB-UVB phototherapy | Intervention Type: DRUG; Name: Adalimumab (Humira); Assigned to Arm(s): Adalimumab (Humira) | Intervention Type: DRUG; Name: Placebo Injection; Assigned to Arm(s): Placebo Injection | Intervention Type: OTHER; Name: NB-UVB phototherapy; Assigned to Arm(s): NB-UVB phototherapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nutrition, Arsenic and Cognitive Function in Children
Brief Summary: The main goals of this study are to evaluate whether supplementation with folate and vitamin B12 to 8 to 10 year old children, in conjunction with reduction in arsenic exposure, can increase arsenic methylation and lower blood arsenic and blood monomethyl arsenic (as previously observed in adults). The investigators will also explore whether folate and B12 can mitigate arsenic-related decrements in cognitive abilities.


Options:
A: Arm Label: folic acid; Type: EXPERIMENTAL; Interventions: Drug: folic acid supplementation | Intervention Type: DRUG; Name: folic acid supplementation; Assigned to Arm(s): folic acid
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Iron (27 mg) - folic acid (600 ug) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multiple micronutrient | Intervention Type: DIETARY_SUPPLEMENT; Name: Iron (27 mg) - folic acid (600 ug); Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Multiple micronutrient; Assigned to Arm(s): 2
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Folic Acid 400 ug; Type: EXPERIMENTAL; Interventions: Dietary Supplement: folic acid | Arm Label: Folic Acid 800 ug; Type: EXPERIMENTAL; Interventions: Dietary Supplement: folic acid | Arm Label: Creatine; Type: EXPERIMENTAL; Interventions: Dietary Supplement: creatine | Arm Label: Creatine + Folic Acid; Type: EXPERIMENTAL; Interventions: Dietary Supplement: creatine + folic acid | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: folic acid; Assigned to Arm(s): Folic Acid 400 ug | Intervention Type: DIETARY_SUPPLEMENT; Name: folic acid; Assigned to Arm(s): Folic Acid 800 ug | Intervention Type: DIETARY_SUPPLEMENT; Name: creatine; Assigned to Arm(s): Creatine | Intervention Type: DIETARY_SUPPLEMENT; Name: creatine + folic acid; Assigned to Arm(s): Creatine + Folic Acid
D: Arm Label: Nutritional Intervention Arm; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin B12, Dietary Supplement: Folic Acid | Arm Label: Control Arm; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin B12; Assigned to Arm(s): Nutritional Intervention Arm | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Control Arm | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic Acid; Assigned to Arm(s): Nutritional Intervention Arm

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nationwide Finnish Registry of Transcatheter and Surgical Aortic Valve Replacement for Aortic Valve Stenosis: FinnValve Registry
Brief Summary: The FinnValve investigators planned a nationwide registry to investigate the early and late outcome of transcatheter aortic valve implantation (TAVI) compared to surgical aortic valve replacement (SAVR) in patients with aortic valve stenosis performed from 2008 to 2017 at five Finnish University Hospitals. Data will be collected in a dedicated electronic case report form.


Options:
A: Arm Label: TAVI cohort; Type: N/A; Interventions: Procedure: Aortic valve replacement | Arm Label: SAVR cohort; Type: N/A; Interventions: Procedure: Aortic valve replacement | Intervention Type: PROCEDURE; Name: Aortic valve replacement; Assigned to Arm(s): SAVR cohort, TAVI cohort
B: Intervention Type: DRUG; Name: daptomycin; Assigned to Arm(s): N/A
C: Arm Label: Guideline treatment with parenteral antibiotics; Type: ACTIVE_COMPARATOR; Interventions: Drug: Guideline treatment with parenteral antibiotics | Arm Label: Oral treatment with antibiotics; Type: EXPERIMENTAL; Interventions: Drug: Oral treatment with antibiotics for endocarditis | Intervention Type: DRUG; Name: Oral treatment with antibiotics for endocarditis; Assigned to Arm(s): Oral treatment with antibiotics | Intervention Type: DRUG; Name: Guideline treatment with parenteral antibiotics; Assigned to Arm(s): Guideline treatment with parenteral antibiotics
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fosfomycin and imipenem | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vancomycin | Intervention Type: DRUG; Name: Fosfomycin and imipenem; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vancomycin; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Psycho-social Support Training by School Teachers on Improving Mental Health and Hope of School Going Adolescents in Earthquake Affected Districts in Nepal
Brief Summary: Adolescents are prone to mental health problems such as post-traumatic stress disorder (PTSD) and depression which could become worse in the aftermath of disasters. However, hope can help adolescents cope with the challenges better. For resource poor disaster prone settings, school teachers can provide timely psycho-social support that could improve mental health and hope among adolescents.

Nepal is a disaster prone country that faced a devastating earthquake in 2015 that claimed thousands of lives and left many homeless which could have affected the mental health of adolescents.This study was conducted in schools of Dhading, a severely earthquake affected district and schools of Myagdi, a least affected district by earthquake in Nepal. The intervention focused on training school teachers on psycho-social support for adolescents.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Psychosocial support training for school teachers | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychosocial support training for school teachers; Assigned to Arm(s): Intervention
B: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Behavioral: The TEA intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: The TEA intervention; Assigned to Arm(s): intervention
C: Arm Label: Empateach Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Empateach | Arm Label: Wait-list control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Empateach; Assigned to Arm(s): Empateach Intervention
D: Arm Label: Obese patients treated with bariatric surgery; Type: EXPERIMENTAL; Interventions: Procedure: Bariatric surgery | Arm Label: Obese patients not treated with bariatric surgery; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Bariatric surgery; Assigned to Arm(s): Obese patients treated with bariatric surgery

Answer: A